Literature DB >> 27535837

Multivalent and Multipathogen Viral Vector Vaccines.

Katharina B Lauer1,2, Ray Borrow3,4, Thomas J Blanchard3,5.   

Abstract

The presentation and delivery of antigens are crucial for inducing immunity and, desirably, lifelong protection. Recombinant viral vectors-proven safe and successful in veterinary vaccine applications-are ideal shuttles to deliver foreign proteins to induce an immune response with protective antibody levels by mimicking natural infection. Some examples of viral vectors are adenoviruses, measles virus, or poxviruses. The required attributes to qualify as a vaccine vector are as follows: stable insertion of coding sequences into the genome, induction of a protective immune response, a proven safety record, and the potential for large-scale production. The need to develop new vaccines for infectious diseases, increase vaccine accessibility, reduce health costs, and simplify overloaded immunization schedules has driven the idea to combine antigens from the same or various pathogens. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes/serogroups in combination (multivalent or polyvalent vaccines). Future multivalent vaccine candidates are likely to be required for complex diseases like malaria and HIV. Other novel strategies propose an antigen combination of different pathogens to protect against several diseases at once (multidisease or multipathogen vaccines).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  multidisease vaccine; multipathogen vaccine; multivalent vaccine; polyvalent vaccine; viral vector vaccine

Mesh:

Substances:

Year:  2017        PMID: 27535837      PMCID: PMC5216423          DOI: 10.1128/CVI.00298-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  86 in total

Review 1.  Manufacturing issues with combining different antigens: a regulatory perspective.

Authors:  L A Falk; J Arciniega; L McVittie
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

2.  Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

Authors:  C I Toogood; J Crompton; R T Hay
Journal:  J Gen Virol       Date:  1992-06       Impact factor: 3.891

Review 3.  Viral vectors as vaccine platforms: deployment in sight.

Authors:  Christine S Rollier; Arturo Reyes-Sandoval; Matthew G Cottingham; Katie Ewer; Adrian V S Hill
Journal:  Curr Opin Immunol       Date:  2011-04-20       Impact factor: 7.486

4.  Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.

Authors:  Samantha Brandler; Claude Ruffie; Valérie Najburg; Marie-Pascale Frenkiel; Hughes Bedouelle; Philippe Desprès; Frédéric Tangy
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

5.  A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.

Authors:  Samantha Brandler; Claude Ruffié; Chantal Combredet; Jean-Baptiste Brault; Valérie Najburg; Marie-Christine Prevost; André Habel; Erich Tauber; Philippe Desprès; Frédéric Tangy
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

6.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

7.  Generation of an infectious cDNA of a highly cardiovirulent coxsackievirus B3(CVB3m) and comparison to other infectious CVB3 cDNAs.

Authors:  C Lee; E Maull; N Chapman; S Tracy; J Wood; C Gauntt
Journal:  Virus Res       Date:  1997-08       Impact factor: 3.303

8.  A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Authors:  Ruth A Karron; Robert B Belshe; Peter F Wright; Bhagvanji Thumar; Barbars Burns; Frances Newman; Joan C Cannon; Juliette Thompson; Theodore Tsai; Maribel Paschalis; Shin-Lu Wu; Yvonne Mitcho; Jill Hackell; Brian R Murphy; Joanna M Tatem
Journal:  Pediatr Infect Dis J       Date:  2003-05       Impact factor: 2.129

9.  Acute myocarditis. Rapid diagnosis by PCR in children.

Authors:  A B Martin; S Webber; F J Fricker; R Jaffe; G Demmler; D Kearney; Y H Zhang; J Bodurtha; B Gelb; J Ni
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

10.  A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression.

Authors:  Hao Chen; Dongyang Wang; Ruiting Xia; Qinwen Mao; Haibin Xia
Journal:  BMC Biotechnol       Date:  2015-02-13       Impact factor: 2.563

View more
  34 in total

Review 1.  Zika virus vaccines.

Authors:  Peter Abbink; Kathryn E Stephenson; Dan H Barouch
Journal:  Nat Rev Microbiol       Date:  2018-10       Impact factor: 60.633

Review 2.  COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.

Authors:  Naim Mahroum; Noy Lavine; Aviran Ohayon; Ravend Seida; Abdulkarim Alwani; Mahmoud Alrais; Magdi Zoubi; Nicola Luigi Bragazzi
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

Review 3.  Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.

Authors:  Sourabh Shukla; He Hu; Hui Cai; Soo-Khim Chan; Christine E Boone; Veronique Beiss; Paul L Chariou; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2020-09-29       Impact factor: 10.431

Review 4.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

Review 5.  Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.

Authors:  Katie Ewer; Sarah Sebastian; Alexandra J Spencer; Sarah Gilbert; Adrian V S Hill; Teresa Lambe
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 6.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 7.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

8.  A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses.

Authors:  Natalie A Prow; Liang Liu; Eri Nakayama; Tamara H Cooper; Kexin Yan; Preethi Eldi; Jessamine E Hazlewood; Bing Tang; Thuy T Le; Yin Xiang Setoh; Alexander A Khromykh; Jody Hobson-Peters; Kerrilyn R Diener; Paul M Howley; John D Hayball; Andreas Suhrbier
Journal:  Nat Commun       Date:  2018-03-26       Impact factor: 14.919

9.  Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.

Authors:  Mariangela Garofalo; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Katarzyna Wanda Pancer; Magdalena Wieczorek; Lukasz Kuryk
Journal:  Vaccines (Basel)       Date:  2020-06-10

Review 10.  Immune-mediated approaches against COVID-19.

Authors:  Helena F Florindo; Ron Kleiner; Daniella Vaskovich-Koubi; Rita C Acúrcio; Barbara Carreira; Eilam Yeini; Galia Tiram; Yulia Liubomirski; Ronit Satchi-Fainaro
Journal:  Nat Nanotechnol       Date:  2020-07-13       Impact factor: 40.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.